Newsflash:
- Better T2DM Glycemic Control Achieved When Pharmacists and Physicians Collaborated
- Progeria Treatment Within Reach? Drug May Target Accelerated Aging Enzyme in Children
- Colitis Nod Puts J&J's Simponi One Step Closer to Blockbuster
- Novo Nordisk Says Completes Hemophilia Drug Trial
- Pfizer Halts Study of Lymphoma Drug Unlikely to Help Survival
- FDA Staff Says Merck's Sleep Drug Effective, Questions Dosage
AstraZeneca Updates on Olaparib and TC-5214 Development Programs
AstraZeneca Press Release (12/20/11)
AstraZeneca has announced that its investigational compound olaparib will not progress into Phase III development for the maintenance treatment of serous ovarian cancer. In addition, AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with major depressive disorder did not meet its primary end point.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
